C肽为1型糖尿病进展期血糖升高提供关键背景信息
随着针对症状前1型糖尿病的疾病修饰疗法获批和研发管线增长,对尚未出现临床症状者进行胰岛自身抗体筛查增加。目前用于定义症状前和症状期1型糖尿病诊断的分期系统基于胰岛自身抗体和血糖状态。本文提出应考虑使用C肽值为血糖提供背景信息,可能改善对临床疾病进展的预测、提高1型糖尿病典型特征的特异性,并更快速识别对疾病修饰疗法的反应。
要点
- C肽可为血糖升高提供背景,改善1型糖尿病进展预测。
- 纳入C肽可提高1型糖尿病特征特异性,减少年龄和胰岛素抵抗等混杂影响。
- C肽有助于更快速识别对疾病修饰疗法的反应。
核心结论
- 应考虑使用C肽值为血糖提供背景信息,以改善1型糖尿病进展预测和疾病修饰疗法反应识别。
主要发现
- 纳入C肽可能更好地预测向临床疾病的进展。
- 纳入C肽可能提高1型糖尿病典型特征的特异性,减少年龄和胰岛素抵抗等对血糖的混杂影响。
- 纳入C肽可能更快速识别对疾病修饰疗法的反应。
临床怎么用
- 在症状前和症状期1型糖尿病评估中,可考虑结合C肽值解读血糖状态。
- C肽值可用于辅助判断1型糖尿病进展风险和疾病修饰疗法反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The regulatory approval and growing pipeline of disease-modifying therapies for presymptomatic type 1 diabetes have sparked an increase in screening for the presence of islet autoantibodies in individuals who may not have yet developed clinical symptoms of disease. The staging system that is currently employed to define type 1 diabetes diagnosis in presymptomatic and symptomatic phases is based on the presence of islet autoantibodies and glycemic status. Here, we make the case to consider using C-peptide values to provide context for glycemia. Inclusion of C-peptide could result in better prediction of progression to clinical disease and more specificity for features typically associated with type 1 diabetes (and, thus, be less susceptible to confounding influences on glycemia like age and insulin resistance). It also could more rapidly identify responses to disease-modifying therapies. The implementation and translation of these findings will be key to long-term success in type 1 diabetes prediction and disease modification strategies.
引用
- Sims EK, Skyler JS, Jacobsen LM, et al. C-Peptide Provides Critical Contextual Insight Into Elevated Glucose Values During Progression to Type 1 Diabetes. Diabetes Care. 2026. PMID: 42060373. doi:10.2337/dci26-0022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。